FDA May Revise MedWatch Reporting Methods For Race, Ethnicity Data
This article was originally published in The Gray Sheet
Executive Summary
FDA is considering revising the way patient race and ethnicity data are collected on MedWatch adverse event reporting forms
You may also be interested in...
Gen/Surg Panel Okays Dermal Fillers 6-3; Minority Patient Studies Proposed
Medicis/Q-Med plan to conduct a 100-patient, Phase IV study to evaluate Restylane non-animal stabilized hyaluronic acid-based wrinkle gel in "people of color," in accordance with FDA panel recommendations
FDA Issues Guidance On Collection Of Race/Ethnicity Data In Clinical Trials
An FDA draft guidance to aid in collection of standardized race and ethnicity information in clinical trials applies to devices as well as drugs
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”